Pipeline hope meets ZEJULA pressure
- Q1 2026 net product revenue fell 10% year over year to $95.6 million.
- ZEJULA is still the top product, but its Q1 sales dropped 39% year over year.
- XACDURO grew 667% year over year, showing that newer launches can help fill the gap.
- VYVGART had a 12% price cut after NRDL renewal, so volume growth must do more work.
- Zoci gives Zai Lab a global oncology shot, but it still needs later trial proof.
A reset after Q1
Zai Lab is in a tougher spot than it was a year ago. Q1 2026 net product revenue was $95.6 million, down 10% from the prior year period. The main issue was ZEJULA, the ovarian cancer drug that remains Zai Lab's largest product. Its sales fell 39% year over year as generic competition changed hospital buying patterns.
The bull case is not gone. XACDURO sales rose 667% year over year in Q1 2026, and NUZYRA, VYVGART, QINLOCK, OPTUNE, AUGTYRO, and soon KarXT give Zai Lab more than one way to grow. Management also pointed to Zoci, a DLL3 antibody drug conjugate for small cell lung cancer, after reporting a 62.5% intracranial ORR in patients with brain metastases. ORR means the share of patients whose tumors shrank by a set amount.
The bear case is that the old cash engine is shrinking faster than the new products can scale. VYVGART also faced a 12% price cut tied to China's National Reimbursement Drug List, or NRDL, so higher patient use may not translate into the same revenue growth. That makes the path to profit less clear.
Finn's scores fit a wait-and-see view. Growth has promise, but current performance and valuation do not give much room for mistakes. The next few quarters need to show that ZEJULA is bottoming, KarXT can launch well, and Zoci can keep showing strong data without new safety problems.
License, approve, sell
Zai Lab usually does not invent every drug from scratch. It licenses promising medicines from global partners, runs local development when needed, seeks Chinese approval, and sells the products in Greater China. This lets Zai Lab bring overseas drugs to Chinese patients faster than a pure discovery company could.
Revenue comes from product sales. A major swing factor is NRDL listing in China, because reimbursement can make a drug easier for patients and hospitals to use. The tradeoff is price pressure. VYVGART's 12% price cut after NRDL renewal is a clear example.
The model costs a lot of money. Zai Lab pays for licenses, clinical trials, regulatory work, sales teams, and launches. The company still has a history of net losses, so it needs steady product growth and careful spending to prove it can reach lasting profit.
Seven sellers, one launch next
ZEJULA
ZEJULA is a PARP inhibitor used as maintenance treatment for ovarian cancer. It was 31.4% of Q1 2026 product revenue, but sales fell 39% year over year.
VYVGART and VYVGART Hytrulo
VYVGART treats generalized myasthenia gravis and CIDP. Q1 2026 sales were pressured by a price change after NRDL renewal, even though volume growth remains an open upside.
NUZYRA
NUZYRA is an antibiotic for community-acquired bacterial pneumonia and certain skin infections. It supplied 17.0% of Q1 2026 product revenue.
XACDURO
XACDURO is an antibiotic for hospital and ventilator-associated pneumonia caused by ABC bacteria. It grew 667% year over year in Q1 2026 after its mainland China launch in January 2025.
OPTUNE
OPTUNE is a medical device that uses Tumor Treating Fields for glioblastoma. It is a meaningful product, but not the main growth story.
QINLOCK
QINLOCK treats advanced gastrointestinal stromal tumors. It helps diversify revenue away from ZEJULA.
AUGTYRO
AUGTYRO treats ROS1-positive non-small cell lung cancer, and the NMPA approved a new NTRK-positive solid tumor indication in December 2025. It is still small in the revenue mix.
KarXT and Zoci
KarXT was approved in China for adult schizophrenia in December 2025, with launch expected in the first half of 2026. Zoci is the larger pipeline swing factor as Zai Lab pushes into global oncology.
Product mix in Q1
Zai Lab reports as one operating segment, so the mix below uses Q1 2026 net product revenue by product. ZEJULA was still the largest line at 31.4%, which keeps concentration risk high.
What could go wrong
ZEJULA erosion
High impact · High oddsZEJULA sales fell 39% year over year in Q1 2026. Management tied the drop to a shift in hospital use after volume-based procurement for generic olaparib. If this is not a short-term shock, Zai Lab loses its biggest product profit pool faster than expected.
China price pressure
High impact · Medium oddsChina's NRDL can raise patient access, but it can also cut price. VYVGART had a 12% price cut after NRDL renewal, and Q1 2026 VYVGART sales fell 3% year over year. Volume must grow enough to offset lower price.
KarXT launch miss
Medium impact · Medium oddsKarXT was approved by the NMPA in December 2025 for schizophrenia in adults, with commercial launch expected in the first half of 2026. The launch matters because Zai Lab needs new products to restart top-line growth. A slow start would make the ZEJULA decline harder to absorb.
Zoci trial disappointment
High impact · Medium oddsZoci is central to the global oncology pivot. Early data included a 62.5% intracranial ORR in small cell lung cancer patients with brain metastases, but early response rates can fade in larger trials. Safety is also a key question for antibody drug conjugates, which carry toxic payloads to cancer cells.
ZEJULA sales investigation
High impact · Medium oddsThe 2025 10-K disclosed that some current and former ZEJULA sales employees are under criminal investigation by Chinese authorities in their personal capacity for alleged medical insurance fraud. The filing says the crime can be prosecuted against individuals and not companies, but the issue can still hurt reputation and operations. Q1 2026 filings did not report a material update.
In one breath
What does Zai Lab do?
Zai Lab brings innovative drugs to Greater China and also builds selected global programs. It licenses many products from partners, gets approvals, and sells them through its own commercial setup.
Why did Zai Lab revenue fall in Q1 2026?
Net product revenue fell 10% year over year in Q1 2026. The main causes were a 39% drop in ZEJULA sales and lower VYVGART revenue after an NRDL-related price adjustment.
What is the biggest upside for ZLAB?
Near term, the upside is that XACDURO, KarXT, VYVGART volume, and other products offset ZEJULA. Longer term, Zoci could matter if later oncology trials confirm the early response data.
What is the biggest risk for ZLAB?
The biggest risk is that ZEJULA keeps falling while newer products ramp too slowly. The ZEJULA sales investigation and China price pressure add more uncertainty.